<DOC>
	<DOCNO>NCT01556685</DOCNO>
	<brief_summary>This cross sectional Phase 4 , multicenter , study AVONEX® JUMTAB® determine frequency IFN induce Neutralizing Antibodies ( Nabs ) . A secondary component long term retrospective observational evaluation conduct measure efficacy , adherence therapy , tolerability , safety subject relapse MS relate antibody status treatment .</brief_summary>
	<brief_title>MATRIX : Measuring Neutralizing Antibodies Patients Treated With Interferon Beta 1a IM , Mexico Colombia</brief_title>
	<detailed_description>The primary objective study evaluate frequency neutralize antibody patient treat IFN beta 1a IM ( Avonex ) IFN beta 1a IM biosimilar formulation ( Jumtab ) . Secondary objective : - Evaluate effect Nabs severity relapse treatment group , measure : - The need duration steroid course - The need duration hospitalization . - To evaluate safety tolerability IFN beta 1a IM treatment [ Avonex Jumtab ] . - To identify genetic profile patient relation predisposition Nab development ( HLA DR4 ( particular HLADRB1* 0401 0408 ) DR16 ( particular HLADRB1* 1601 ) - At select site : To evaluate influence interferon Nabs activation neopterin</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>To eligible entry study , candidate must meet following eligibility criterion time selection : No limitation age , EDSS disease parameter apply . Subject MS Subjects treat IFN beta 1a IM ( Avonex ) biosimilar formulation IFN beta 1a IM ( Jumtab ) line local prescription information The IFN beta 1a IM ( Avonex Jumtab ) treatment first disease modify treatment The subject treat drug least 18 month maximum 3 year Candidates exclude study entry follow exclusion criterion exist time selection : No informed consent Patients combination therapy ( IFN + immunosuppressive therapy ) Patients pretreated immunosuppressive therapy Treatment investigational product , include investigational symptomatic therapy MS ( e.g. , 4Aminopyridine ) investigational therapy NonMS indication , review period . NOTE : subject may receive investigational symptomatic therapy MS time prior evaluation period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>